clinical trial · NCT04163016
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
UCB Biopharma SRL·phase1·completed·n = 22
Rheumatoid ArthritisPsoriatic ArthritisCrohn's DiseaseAxial SpondyloarthritisPlaque PsoriasisPharmacokinetics of certolizumab pegol
brief summary
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
started
Jun 19, 2020
primary completion
May 23, 2023
completion
May 23, 2023
last updated
Sep 19, 2024
official title
A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol